Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA)

Abstract

Dear Editor, The increased understanding of atopic dermatitis (AD) pathophysiology has shed light on the underlying immuno- logical mechanisms and spurred the development of novel, more precisely targeted therapies.1 As new agents become available, assessing their added value is advisable. Yet the value of novel health interventions sometimes remains largely unmeasured and inadequately understood. 2 Value assessment is challenging since it involves assessing the ex- tent to which it meets current unmet needs. Therefore, it is necessary to establish the most relevant health outcomes from different stakeholders' perspectives. The main goal of AD treatment is to establish and sus- tain disease control, allowing patients to be fully functional in their lives. 3 Therefore, the value of novel treatments should be assessed not only according to their effectivity in target skin clearance but also improving patient-reported outcomes.